Diabetes Mellitus, Insulin-Dependent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Notably, we found that the SNP with the highest association with T1D susceptibility and IgG autoantibody reactivity (rs1950942) was also associated with anti-GAD IgM reactivity in T1D patients (P = 5.98E-03) and in non-affected parents (P = 4.17E-03).
|
28534223 |
2017 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
A 29-year-old man was observed to develop insulin-dependent diabetes mellitus following a 5-month treatment with recombinant alpha-2b-interferon for chronic hepatitis C. After the onset of the disease, serum samples that had, respectively, been collected before therapy commencement, at month 3, and at the onset of insulin-dependent diabetes mellitus were tested for islet-cell (ICA-IgG), glutamic acid decarboxylase (GAD-Abs), IA2 (IA2-Abs) and insulin (IA-Abs) autoantibodies.
|
9551692 |
1998 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The distribution of INS-VNTR was no different between Type 1 diabetes and Type 2 diabetes with GAD Ab.
|
11606170 |
2001 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluate the added value of screening anti-ZnT8 antibodies (ZnT8A) in addition to the classical anti-GAD (GADA) and anti-IA-2 (IA-2A) antibodies for the diagnosis of type-1 diabetes (T1D) within a large cohort of both children and adults.
|
29288641 |
2018 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
We measured insulin autoantibodies (IAAs), GAD autoantibodies (GAAs), and ICA512bdc autoantibodies (ICA512bdcAAs) by radioassay, in addition to ICAs, in 882 first-degree relatives of patients with type I diabetes, 50 of whom later developed diabetes with a median follow-up of 2.0 years (maximum 11.3 years).
|
8666144 |
1996 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
The emergence of type 1 diabetes-associated autoantibodies in serum (autoantibodies to GAD, insulinoma-associated protein 2, insulin and islet cells) was monitored during prospective follow-up.
|
28866779 |
2018 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that considerable heterogeneity exists in Scandinavian subjects with EOD; 24% had MODY or maternally inherited diabetes and deafness, and approximately 60% were GAD antibody positive or had type 1 diabetes-associated HLA genotypes.
|
11978663 |
2002 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to document prevalence and clinical presentations of seropositivities for glutamate decarboxylase (GAD)-antibody, celiac's disease (CD) and autoimmune thyroiditis (AIT) in adult patients with type 1 diabetes mellitus (T1DM), and their first-degree relatives.
|
18218004 |
2009 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peptides of proinsulin and GAD shown to be recognized by CD4+ T cells of type 1 diabetes patients have been selected from the literature and modified with Ii-Key.
|
21512962 |
2011 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated whether HLA-A*24 typing complements screening for HLA-DQ and for antibodies (Abs) against insulin, GAD, IA-2 (IA-2A), and zinc transporter-8 (ZnT8A) for prediction of rapid progression to type 1 diabetes (T1D).
|
23160529 |
2013 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, increased cellular immunity to the mid region of GAD67 was a marker of late pre-clinical IDDM, but appears to reflect a more general, transient state of cellular immune hyperresponsiveness.
|
9185878 |
1997 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes.
|
8816974 |
1996 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the association of HLA class II (DR and DQ) alleles and haplotypes with the presence of GAD and IA-2 autoantibodies in T1D.
|
21490167 |
2011 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously demonstrated that GAD and IA-2 antibodies potentially identify different subsets of IDDM patients.
|
8897011 |
1996 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, we found a significant correlation between autoimmune-related type 1 diabetes with HLA DR9 and detection of GAD-reactive Th1 (T helper 1)-type cells.
|
17130562 |
2006 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
A European Phase III trial of GAD formulated with aluminium hydroxide (GAD-alum) failed to reach its primary endpoint (preservation of stimulated C-peptide secretion from baseline to 15 months in type 1 diabetes patients), but subgroup analysis showed a clinical effect when participants from Nordic countries were excluded, raising concern as to whether the mass vaccination of the Swedish and Finnish populations with the Pandemrix influenza vaccine could have influenced the study outcomes.
|
28357504 |
2017 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
The most frequent comorbidity of anti-GAD positive patients was diabetes mellitus type 1 (n=8).
|
29579551 |
2018 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was an association between T cell reactivity against GAD and HLA DR9 in Japanese type 1 diabetes.
|
15699491 |
2004 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
The risk was increased in girls (adjusted HR 2.0; 95% CI 1.2-3.4; p = 0.008), in children who had multiple first-degree family history of type 1 diabetes (adjusted HR 3.3; 95% CI 1.4-8.0; p = 0.006) and in children who also had antibodies to GAD (adjusted HR 3.0; 95% CI 1.5-5.9; p = 0.001).
|
19018508 |
2009 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
During the median follow-up time of 57 months, 350 children developed at least one persistent IA (GAD antibody, IA-2A, or micro insulin autoantibodies) and 84 of them progressed to T1D.
|
25422107 |
2015 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
HLA-DRB1 allele typing revealed that NIDDM-SF patients positive for anti-GAD were significantly associated with DRB1*0901 (RR = 2.81, P < 0.01), which is one of the susceptible alleles to IDDM.
|
9344701 |
1997 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
GAD autoantibody affinity and epitope specificity identify distinct immunization profiles in children at risk for type 1 diabetes.
|
17325256 |
2007 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, the T allele was significantly associated with elevated levels of HbA1c, anti-GAD, and anti-insulin antibodies (p < 0.001) and a lower concentration of C-peptide (p < 0.001) in T1D children.
|
29611765 |
2018 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although it has been confirmed that insulin dependent diabetes mellitus (IDDM) is a kind of autoimmune disease, islet cell autoantibodies (ICAs), insulin autoantibodies (IAA) and anti-GAD-glutamic acid decardaxylase antibodies have been found in the sera of patients with IDDM and immunotherapies have been used in some patients with IDDM, yet the manner in which the dysfunctional immunosystem acts on beta cells and causes damage to them remains to be clarified.
|
8143505 |
1993 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
GAD is a major islet cell autoantigen in human type 1 diabetes mellitus.
|
8149657 |
1994 |